4.6 Article

Insights into the Motif Preference of APOBEC3 Enzymes

Journal

PLOS ONE
Volume 9, Issue 1, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0087679

Keywords

-

Funding

  1. Australian National Health and Medical Research Council (NHMRC)
  2. NHMRC

Ask authors/readers for more resources

We used a multivariate data analysis approach to identify motifs associated with HIV hypermutation by different APOBEC3 enzymes. The analysis showed that APOBEC3G targets G mainly within GG, TG, TGG, GGG, TGGG and also GGGT. The G nucleotides flanked by a C at the 39 end (in + 1 and + 2 positions) were indicated as disfavoured targets by APOBEC3G. The G nucleotides within GGGG were found to be targeted at a frequency much less than what is expected. We found that the infrequent G-to-A mutation within GGGG is not limited to the inaccessibility, to APOBEC3, of poly Gs in the central and 3'polypurine tracts (PPTs) which remain double stranded during the HIV reverse transcription. GGGG motifs outside the PPTs were also disfavoured. The motifs GGAG and GAGG were also found to be disfavoured targets for APOBEC3. The motif-dependent mutation of G within the HIV genome by members of the APOBEC3 family other than APOBEC3G was limited to GA -> AA changes. The results did not show evidence of other types of context dependent G-to-A changes in the HIV genome.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Multidisciplinary Sciences

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Adam K. Wheatley, Jennifer A. Juno, Jing J. Wang, Kevin J. Selva, Arnold Reynaldi, Hyon-Xhi Tan, Wen Shi Lee, Kathleen M. Wragg, Hannah G. Kelly, Robyn Esterbauer, Samantha K. Davis, Helen E. Kent, Francesca L. Mordant, Timothy E. Schlub, David L. Gordon, David S. Khoury, Kanta Subbarao, Deborah Cromer, Tom P. Gordon, Amy W. Chung, Miles P. Davenport, Stephen J. Kent

Summary: The durability of infection-induced SARS-CoV-2 immunity has major implications for reinfection and vaccine development. Antibody, B cell, and T cell responses decline over the first 4 months post-infection, while S-specific IgG(+) memory B cells consistently accumulate. The study suggests that natural infection may only provide transient protection at a population level, highlighting the need for more immunogenic and durable vaccines.

NATURE COMMUNICATIONS (2021)

Article Medicine, Research & Experimental

CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification

Afam A. Okoye, Derick D. Duell, Yoshinori Fukazawa, Benjamin Varco-Merth, Alejandra Marenco, Hannah Behrens, Morgan Chaunzwa, Andrea N. Selseth, Roxanne M. Gilbride, Jason Shao, Paul T. Edlefsen, Romas Geleziunas, Mykola Pinkevych, Miles P. Davenport, Kathleen Busman-Sahay, Michael Nekorchuk, Haesun Park, Jeremy Smedley, Michael K. Axthelm, Jacob D. Estes, Scott G. Hansen, Brandon F. Keele, Jeffery D. Lifson, Louis J. Picker

Summary: The study found that CD8+ T cell depletion did not significantly affect the control of SIV reactivation during ART, but after ART cessation, rhesus macaques with CD8+ T cell depletion showed a significant increase in post-ART plasma viremia.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury, Deborah Cromer, Arnold Reynaldi, Timothy E. Schlub, Adam K. Wheatley, Jennifer A. Juno, Kanta Subbarao, Stephen J. Kent, James A. Triccas, Miles P. Davenport

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Article Immunology

Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial.

Deborah Cromer, Arnold Reynaldi, Megan Steain, James A. Triccas, Miles P. Davenport, David S. Khoury

Summary: The vaccine candidate CVnCoV (CUREVAC) exhibited lower efficacy compared to other mRNA vaccines in a recent phase 3 trial, which can be attributed to the dosage used and the presence of SARS-CoV-2 variants. The neutralizing antibody response induced by the vaccine can predict the low efficacy.

CLINICAL INFECTIOUS DISEASES (2022)

Article Immunology

Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design

Jillian S. Y. Lau, Deborah Cromer, Mykola Pinkevych, Sharon R. Lewin, Thomas A. Rasmussen, James H. McMahon, Miles P. Davenport

Summary: This study used mathematical models to explore ways to improve ATI study design to maximize statistical power and minimize risks to participants.

JOURNAL OF INFECTIOUS DISEASES (2022)

Article Infectious Diseases

Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in mice

Arya SheelaNair, Aleksandra S. Romanczuk, Rosemary A. Aogo, Rohit Nemai Haldar, Lianne I. M. Lansink, Deborah Cromer, Yandira G. Salinas, R. Kiplin Guy, James S. McCarthy, Miles P. Davenport, Ashraful Haque, David S. Khoury

Summary: This study compared the effects of different anti-malarial drugs on mice infected with malaria. The results showed that different drugs varied in their ability to reduce parasite count and had different mechanisms of action. This suggests that although the parasite clearance curves may be similar, the drugs have different capacities to inhibit, kill, and clear parasites.

MALARIA JOURNAL (2022)

Article Multidisciplinary Sciences

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

Sandile Cele, Laurelle Jackson, David S. Khoury, Khadija Khan, Thandeka Moyo-Gwete, Houriiyah Tegally, James Emmanuel San, Deborah Cromer, Cathrine Scheepers, Daniel G. Amoako, Farina Karim, Mallory Bernstein, Gila Lustig, Derseree Archary, Muneerah Smith, Yashica Ganga, Zesuliwe Jule, Kajal Reedoy, Shi-Hsia Hwa, Jennifer Giandhari, Jonathan M. Blackburn, Bernadett Gosnell, Salim S. Abdool Karim, Willem Hanekom, Anne von Gottberg, Jinal N. Bhiman, Richard J. Lessells, Mahomed-Yunus S. Moosa, Miles P. Davenport, Tulio de Oliveira, Penny L. Moore, Alex Sigal

Summary: The study found that the Omicron variant has reduced neutralizing effectiveness in individuals vaccinated with Pfizer BNT162b2, but those who had previously been infected with SARS-CoV-2 showed better neutralization against Omicron.

NATURE (2022)

Article Immunology

Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+ T cell memory

Kathleen M. Wragg, Wen Shi Lee, Marios Koutsakos, Hyon-Xhi Tan, Thakshila Amarasena, Arnold Reynaldi, Grace Gare, Penny Konstandopoulos, Kirsty R. Field, Robyn Esterbauer, Helen E. Kent, Miles P. Davenport, Adam K. Wheatley, Stephen J. Kent, Jennifer A. Juno

Summary: Wragg and colleagues tracked clonal populations of spike-specific CD4(+) cT(FH) cells using MHC class II tetramers and TCR beta sequencing in convalescent individuals with COVID-19 or SARS-CoV-2-vaccinated individuals. They found that both infection and vaccination induced CD4(+) T cell responses to the spike protein and that these responses correlated with neutralizing antibodies. Secondary exposure led to the recall of CD4(+) T cells with a transitory CXCR3(+) phenotype and expansion of cT(FH) cells temporarily expressing ICOS, CD38, and PD-1. The study demonstrates that stable pools of cT(FH) and memory CD4(+) T cells established by infection and/or vaccination can be efficiently recalled and may contribute to long-term protection against SARS-CoV-2.

NATURE IMMUNOLOGY (2022)

Editorial Material Cell Biology

Nice and slow make the germinal centers go: measured and escalating antigen delivery enhance durability and quality of humoral immune responses against HIV-1

Hyon-Xhi Tan, Miles P. Davenport, Stephen J. Kent, Adam K. Wheatley

IMMUNOLOGY AND CELL BIOLOGY (2022)

Article Multidisciplinary Sciences

Early microbial exposure shapes adult immunity by altering CD8+T cell development

Cybelle Tabilas, David S. Iu, Ciaran W. P. Daly, Kristel J. Yee Mon, Arnold Reynaldi, Samantha P. Wesnak, Jennifer K. Grenier, Miles P. Davenport, Norah L. Smith, Andrew Grimson, Brian D. Rudd

Summary: Microbial exposure during development can have long-lasting effects on an individual's health, but how early microbial exposure leads to permanent changes in the immune system is still unclear. This study shows that early microbial exposure results in the preferential expansion of specific CD8+ T cell populations, which persist and provide enhanced immune protection against intracellular pathogens. Interestingly, this microbial education occurs during thymic development and involves changes in epigenetic programming.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Article Biochemistry & Molecular Biology

Predicting the efficacy of variant-modified COVID-19 vaccine boosters

David S. Khoury, Steffen S. Docken, Kanta Subbarao, Stephen J. Kent, Miles P. Davenport, Deborah Cromer

Summary: Booster vaccination is necessary to combat waning immunity and variants of SARS-CoV-2. Data on neutralization titers from multiple sources suggest that using ancestral vaccines can enhance protection against symptomatic and severe disease caused by variant viruses. Variant-modified vaccines may provide additional benefits. This study provides evidence-based guidance for future COVID-19 vaccine regimens.

NATURE MEDICINE (2023)

Article Multidisciplinary Sciences

Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis

Deborah Cromer, Megan Steain, Arnold Reynaldi, Timothy E. Schlub, Shanchita R. Khan, Sarah C. Sasson, Stephen J. Kent, David S. Khoury, Miles P. Davenport

Summary: The study demonstrates a strong correlation between neutralising antibody titres and vaccine effectiveness against symptomatic and severe COVID-19. Predicted neutralising antibody titres are strongly correlated with observed vaccine effectiveness, and the loss of neutralising antibodies over time and to new variants is predictive of observed vaccine protection against severe COVID-19.

NATURE COMMUNICATIONS (2023)

Article Immunology

Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?

Stephen J. Kent, David S. Khoury, Arnold Reynold, Jennifer A. Juno, Adam K. Wheatley, Eva Stadler, E. John Wherry, James Triccas, Sarah C. Sasson, Deborah Cromer, Miles P. Davenport

Summary: Understanding the role of T cells in SARS-CoV-2 infection is crucial for the design of next-generation vaccines. This perspective discusses the challenges in determining the causal relationship between vaccine-induced T cell immunity and protection from COVID-19, and proposes an approach to gather evidence and clarify the role of vaccine-induced T cell memory in protecting against severe COVID-19.

NATURE REVIEWS IMMUNOLOGY (2022)

Article Immunology

Parasite Viability as a Superior Measure of Antimalarial Drug Activity in Humans

Maria Rebelo, Rebecca Pawliw, Jeremy Gower, Lachlan Webb, Hayley Mitchell, Zuleima Pava, Rebecca E. Watts, Miles P. Davenport, James S. McCarthy, David S. Khoury

Summary: This study found that viable parasites in artemisinin-sensitive infections decreased to <0.1% of baseline within 8 hours after artesunate administration, while the total number of circulating parasites measured with quantitative polymerase chain reaction remained unchanged. In artemisinin-resistant infections over the same interval, viable parasites declined to 51.4% of baseline. These results suggest that the in vivo drug activity of artesunate is quicker than previously reported based on parasite clearance half-life.

JOURNAL OF INFECTIOUS DISEASES (2021)

Review Immunology

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

Deborah Cromer, Jennifer A. Juno, David Khoury, Arnold Reynaldi, Adam K. Wheatley, Stephen J. Kent, Miles P. Davenport

Summary: The duration of immunity to COVID-19 and the risk of reinfection remain unclear. Immunity is crucial for long-term control of the pandemic, but studies suggest a decline in antibody responses and an increase in documented cases of reinfection with SARS-CoV-2. Understanding memory responses and immune control dynamics is essential for designing vaccines and predicting the future trajectory of the pandemic.

NATURE REVIEWS IMMUNOLOGY (2021)

No Data Available